» Articles » PMID: 8657216

Survival of Medicare Patients After Enrollment in Hospice Programs

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1996 Jul 18
PMID 8657216
Citations 101
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Each year more than 220,000 Medicare beneficiaries receive care from hospice programs designed to enhance the quality of the end of life. Enrollment requires certification by a physician that the patient has a life expectancy of less than six months. We examined how long before death patients enrolled in hospice programs.

Methods: Using 1990 Medicare claim data, we analyzed the characteristics and survival of 6451 hospice patients followed for a minimum of 27 months with respect to mortality.

Results: The patients' mean age was 76.4 years; 92.4 percent were white. Half the patients were women, and 80.2 percent had cancer of some type. The most common diagnoses were lung cancer (21.4 percent), colorectal cancer (10.5 percent), and prostate cancer (7.4 percent). The median survival after enrollment was only 36 days, and 15.6 percent of the patients died within 7 days. At the other extreme, 14.9 percent of the patients lived longer than six months. Survival varied substantially according to diagnosis, even after adjustment for age and co-existing conditions. The unadjusted survival after enrollment was shortest for those with renal failure, those with leukemia or lymphoma, and those with liver or biliary cancer; it was longest for those with chronic lung disease, those with dementia, and those with breast cancer. Patients at for-profit, larger, outpatient, or newer hospices lived longer after enrollment than those in other types of hospice programs.

Conclusions: Most patients who enter hospice care do so late in the course of their terminal illnesses. The timing of enrollment in hospice programs varies substantially with the characteristics of the patients and the hospices.

Citing Articles

Factors Associated With Long Survival in Patients With Cancer Admitted to Palliative Care: An Exploratory Study.

Ferraz-Goncalves J, Alves A, Silva A, Valente A, Pina A, Lima A J Palliat Care. 2024; 39(3):244-252.

PMID: 38374645 PMC: 11097604. DOI: 10.1177/08258597241231005.


Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement.

Heo D, Yoo S, Keam B, Yoo S, Koh Y J Hosp Palliat Care. 2023; 25(1):1-11.

PMID: 37674892 PMC: 10180009. DOI: 10.14475/jhpc.2022.25.1.1.


Use of Advance Directives in US Veterans and Non-Veterans: Findings from the Decedents of the Health and Retirement Study 1992-2014.

Tung H, Yeh M Healthcare (Basel). 2023; 11(13).

PMID: 37444658 PMC: 10341334. DOI: 10.3390/healthcare11131824.


Public Health and Palliative Care.

Cross S, Kavalieratos D Clin Geriatr Med. 2023; 39(3):395-406.

PMID: 37385691 PMC: 10571066. DOI: 10.1016/j.cger.2023.04.003.


Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.

Chongqing T, Sini L, Xiaohui Z, Liubao P, Ye P, Shuxia Q Front Pharmacol. 2021; 12:802942.

PMID: 34970153 PMC: 8712714. DOI: 10.3389/fphar.2021.802942.